Ann: Invex Granted Key European Patent for Exenatide, page-47

lol I aint selling at $3, Im waiting for buyout at $10.

I think as many have stated before the main reason for the discount is the confusion surrounding FDA/EMA
Even Tom states it below, EU constitutes 60%.
I guarantee the moment they clear up the FDA/EMA discussions this will triple. Its just waiting to then. After that we can slowly continue our accent up to the same valuations as the peers mentioned within the 400 mill mark as we draw closer to takeover.
“Our discounted enterprise value of $25 million does not reflect Invex’s stage of development or the market opportunity of IIH, particularly when you consider the EU constitutes 60% of the addressable market for IIH and the EMA has provided protocol assistance confirming a single phase three trial will be sufficient to support an application for market approval, subject to demonstrating clinical efficacy and safety. Meanwhile we continue to progress similar discussions with the FDA” he claimed.